The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care.

The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

Dec 11, 2024 · Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor …

Jun 18, 2025 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

May 11, 2025 · In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum …

Dec 31, 2024 · The American Public’s Disengagement With Highly Pathogenic Avian Influenza (HPAI): Considerations for Vaccination and Dietary Changes, American Journal of Public …

Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase …

Nov 16, 2024 · Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …

Feb 1, 2024 · The New England Journal of Medicine (NEJM) offers multiple access levels to content and features at NEJM.org including:. NEJM Articles (1990–Present) Features & …

Dec 7, 2024 · B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of …